Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Scientists from the Miller School of Medicine at the University of Miami have reported their recent work to develop small-molecule inhibitors of the CD40-CD40L (CD154) costimulatory protein-protein ...

近年来，CD40和CD40L逐渐走入科研的前沿，成为免疫系统研究的重要焦点。作为一种跨膜蛋白，CD40在抗原呈递细胞表面大放异彩，尤其在B细胞、巨噬 ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Eledon Pharmaceuticals (ELDN) announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a key component of the ...

Further support for this concept comes from animal models of autoimmunity and transplantation, where treatments based on costimulation blockade, in particular CD40 ligand (CD40L)-specific ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. | Novartis has finally given up on iscalimab after deciding that the ...

The work focuses on the interaction of B cells and T cells in the body's immune system via two proteins—CD40 on B cells and CD40L on T cells—in an immune deficiency disease called X-linked ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...